

Matthias Christgen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2821897/matthias-christgen-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

70
papers

1,368
citations

19
h-index

36
g-index

72
ext. papers

1,770
ext. citations

5
avg, IF

4.07
L-index

#	Paper	IF	Citations
70	Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC). <i>Cancer Research</i> , 2022 , 82, P1-02-09-P1-02-09	10.1	
69	The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.. <i>British Journal of Cancer</i> , 2022 ,	8.7	1
68	Abstract PD10-11: Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype. <i>Cancer</i>	10.1	1
67	Abstract P2-13-03: KEYRICHD-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype. <i>Cancer Research</i> , 2022 , 82, P2-13-03-P2-13-03	10.1	
66	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102759	2.2	2
65	TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. <i>Cancer Medicine</i> , 2021 , 10, 8581-8594	4.8	3
64	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions. <i>Cancers</i> , 2021 , 13,	6.6	3
63	Chromosome 2q gain and epigenetic silencing of GATA3 in microglandular adenosis of the breast. <i>Journal of Pathology: Clinical Research</i> , 2021 , 7, 220-232	5.3	1
62	Transcription factor AP-2beta in development, differentiation and tumorigenesis. <i>International Journal of Cancer</i> , 2021 , 149, 1221-1227	7.5	1
61	Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 504-504	2.2	1
60	Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. <i>Cancers</i> , 2021 , 13,	6.6	8
59	Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2021 ,	5.3	2
58	E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. <i>Modern Pathology</i> , 2020 , 33, 2483-2498	9.8	7
57	Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. <i>Npj Breast Cancer</i> , 2020 , 6, 21	7.8	24
56	De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 515-515	2.2	5
55	ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS601-TPS601	2.2	4
54	The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920973130	5.4	9

53	Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. <i>Cancer</i> , 2020 , 126, 4847-4858	6.4	15
52	Cardiac Phlegmon: Infectious Endocarditis Causing Ventricular Wall Rupture. <i>The Thoracic and Cardiovascular Surgeon Reports</i> , 2020 , 9, e51-e54	0.3	
51	West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 799-808	2.2	41
50	Lobular neoplasia and invasive lobular breast cancer: Inter-observer agreement for histological grading and subclassification. <i>Pathology Research and Practice</i> , 2019 , 215, 152611	3.4	2
49	ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS596-TPS596	2.2	
48	ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling. <i>Genes Chromosomes and Cancer</i> , 2019 , 58, 175-185	5	17
47	CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer. <i>Journal of Pathology</i> , 2018 , 245, 373-383	9.4	16
46	Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2. <i>Laboratory Investigation</i> , 2018 , 98, 117-129	5.9	18
45	Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018 , 473, 577-582	5.1	8
44	Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12102-12102	2.2	1
43	Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 573-573	2.2	
42	Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 572-572	2.2	
41	Estrogen receptor (ESR1) mutation in bone metastases from breast cancer. <i>Modern Pathology</i> , 2018 , 31, 56-61	9.8	16
40	De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early DC/HER2- and Hormone Receptor-Positive Phase II Randomized Trial Efficacy, Safety, and Biomarker Analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3049-3054	2.2	72
39	Subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid-papillary carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2017 , 3, 191-202	5.3	16
38	Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. <i>Breast Cancer Research and Treatment</i> , 2017 , 165, 573-583	4.4	100
37	Histologisches Grading beim Mammakarzinom. <i>Wiener Klinisches Magazin: Beilage Zur Wiener Klinischen Wochenschrift</i> , 2017 , 20, 86-93	0	
36	Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC-4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 504-504	2.2	10

35	Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 573-573	2.2	2
34	Results of multicenter phase II WSG Neo-Predict trial: Predictive markers for evaluation of response to neoadjuvant paclitaxel+trastuzumab+lapatinib in HER2-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 582-582	2.2	
33	Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 469, 191-201	5.1	8
32	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2341-9	2.2	185
31	Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab + weekly paclitaxel in HER2+/HR-early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 518-518	2.2	6
30	Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2-early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 556-556	2.2	3
29	Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis. <i>Oncotarget</i> , 2016 , 7, 82733-82740	3.3	10
28	Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 557-557	2.2	1
27	Lobular breast cancer: Clinical, molecular and morphological characteristics. <i>Pathology Research and Practice</i> , 2016 , 212, 583-97	3.4	65
26	Lobular breast cancer: molecular basis, mouse and cellular models. <i>Breast Cancer Research</i> , 2015 , 17, 16	8.3	32
25	The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer. <i>Human Pathology</i> , 2015 , 46, 1341-9	3.7	34
24	Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. <i>Science Translational Medicine</i> , 2015 , 7, 315ra188	17.5	177
23	Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells. <i>PLoS ONE</i> , 2015 , 10, e0136845	3.7	22
22	High frequency of lobular breast cancer in distant metastases to the orbit. <i>Cancer Medicine</i> , 2015 , 4, 1044-1048	4.1	40
21	Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1032-1032	2.2	6
20	Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 506-506	2.2	12
19	Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 524-524	2.2	1
18	Oncogenic PIK3CA mutations in lobular breast cancer progression. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 69-80	5	27

17	IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype. <i>Cancer Science</i> , 2013 , 104, 1726-30	6.9	12
16	Is upregulation of BCL2 a determinant of tumor development driven by inactivation of CDH1/E-cadherin?. <i>PLoS ONE</i> , 2013 , 8, e73062	3.7	6
15	ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells. <i>Cancer Letters</i> , 2012 , 315, 153-60	9.9	30
14	Detection of putative cancer stem cells of the side population phenotype in human tumor cell cultures. <i>Methods in Molecular Biology</i> , 2012 , 878, 201-15	1.4	14
13	IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes. <i>Laboratory Investigation</i> , 2012 , 92, 1635-47	5.9	19
12	Nuclear Kaiso expression is associated with high grade and triple-negative invasive breast cancer. <i>PLoS ONE</i> , 2012 , 7, e37864	3.7	37
11	Limited Value of KAI1/CD82 Protein Expression as a Prognostic Marker in Human Gastric Cancer. <i>Disease Markers</i> , 2012 , 32, 337-342	3.2	5
10	Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 552-552	2.2	1
9	Down-regulation of the fetal stem cell factor SOX17 by H33342: a mechanism responsible for differential gene expression in breast cancer side population cells. <i>Journal of Biological Chemistry</i> , 2010 , 285, 6412-8	5.4	16
8	Reply to: Letter to the editor from Dr. Geradts. <i>International Journal of Cancer</i> , 2009 , 124, 2245-2245	7.5	
7	Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer. <i>Journal of Pathology</i> , 2009 , 217, 620-32	9.4	27
6	Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer. <i>Cancer Science</i> , 2009 , 100, 1767-71	6.9	14
5	KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer. <i>International Journal of Cancer</i> , 2008 , 123, 2239-46	7.5	27
4	Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. <i>Molecular and Cellular Biochemistry</i> , 2007 , 306, 201-12	4.2	73
3	MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. <i>Cancer Biology and Therapy</i> , 2007 , 6, 1355-7	4.6	30
2	Stable expression of temperature-sensitive p53: a suitable model to study wild-type p53 function in pancreatic carcinoma cells. <i>Oncology Reports</i> , 2006 , 16, 575-9	3.5	3
1	Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells. <i>Cancer Letters</i> , 2005 , 227, 193-200	9.9	17